Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients

Launched by IRCCS BURLO GAROFOLO · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain tests can help predict heart injuries in children and teenagers receiving a specific type of cancer treatment called Anthracycline chemotherapy. Researchers are looking at echocardiography, which is a type of ultrasound that checks how well the heart is working, and blood tests that measure heart-related proteins. This study aims to find out if these tests can help identify heart problems early in young patients who are about to start their treatment.

To participate in the trial, children and teenagers aged 0 to 18 who have been diagnosed with cancer and are starting Anthracycline therapy may be eligible, but they must have normal heart function before starting the treatment. However, those who have had previous treatments with Anthracycline, bone marrow transplants, or certain heart conditions will not be included. Participants can expect to undergo heart tests before and during their treatment, which will help doctors understand the effects of the chemotherapy on their heart health. This information could be important for ensuring safer cancer treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Paediatric oncological patients 0-18 years
• • Planned start of anthracycline therapy
• • Normal left ventricular systolic function according to International Guidelines before the treatment with AC
• Exclusion Criteria:
• • Previous anthracycline treatment, bone marrow transplantation or chest radiation
• * Pre-anthracycline treatment echocardiographic evidence of:
• • More than mild pericardial effusion
• • More than mild mitral regurgitation
• • Poor echocardiographic acoustic window